Ryan J. Attwood; Kerry L. LaPlante Disclosures Am J Health Syst Pharm. 2007;64 (22):2335-2348.

Key to the re-design is to enable vancomycin to tackle bacteria in different ways. By having more than one mechanism of attack this means that it is harder for bacteria to develop resistance. The ...

Despite vancomycin's performance against placebo, both options had relatively high CDI recurrence rates 8 weeks after treatment completion in 81 patients randomized to either prophylactic oral ...

Vancomycin-based infusion was also associated with a higher risk for device failure (16.9% vs 9.6% for non-recipients, P <0.001).

An adverse event was reported in 613 patients (303 [15.1%] in the vancomycin group and 310 [15.3%] in the placebo group); 70 patients had events that were deemed by the site primary investigator ...

Fecal microbiota transplantation was not inferior to vancomycin for the treatment of primary Clostridioides difficile infection, suggesting it could be a first-line option, according to research ...

Recurrent C. diff emerged in 17 of 39 participants receiving vancomycin (43.6%) versus 24 of 42 receiving placebo (57.1%), an absolute difference of −13.5 percentage points (95% CI, −35.1% to ...

The administration of β-lactams prior to vancomycin is associated with reduced risk of in-hospital mortality among patients with sepsis, according to results of a study published in Clinical ...